Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 100

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 100
---
 our critical accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2024.

26

Results of Operations

Comparison of the Three Months Ended March 31, 2025 and 2024 

Revenues

Revenues consist primarily of net product sales of our commercial products in the U.S., supplemented by royalty and licensing revenues from our collaborative licensing arrangements. The following table provides information regarding our revenues during the three months ended March 31, 2025 (dollars in thousands):Three Months Ended March 31,Change20252024AmountPercentNet product salesQelbree$64,745 $45,104 $19,641 44%GOCOVRI30,689 26,562 4,127 16%APOKYN14,976 16,649 (1,673)(10)%Trokendi XR12,801 15,989 (3,188)(20)%Oxtellar XR10,198 26,943 (16,745)(62)%Other(1)8,579 7,214 1,365 19%Total net product sales141,988 138,461 3,527 3%Royalty, licensing and other revenues7,836 5,183 2,653 51%Total revenues$149,824 $143,644 $6,180 4%___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Net Product Sales

Net product sales were $142.0 million and $138.5 million for the three months ended March 31, 2025 and 2024, respectively. The increase was primarily due to increases in net product sales from Qelbree and GOCOVRI due to higher volume and higher price partially offset by the decline in net product sales of Oxtellar XR and Trokendi XR due to generic erosion.

Adjustments related to prior year sales for the three months period ended March 31, 2025 is less than 5% of net product sales. The majority of the adjustments is attributable to Qelbree, reflecting favorable actual returns experienced in 2025. As a result, the Company changed its estimated provision for product returns based on the most recent experience. Adjustments related to prior year sales for the three months period ended March 31, 2024 was less than 1% of net product